Ustekinumab-Aauz vs Ustekinumab — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Interleukin-12 Antagonist

Ustekinumab-Aauz

Brand: Otulfi

First FDA approval: 2024-02-22

Interleukin-12 Antagonist

Ustekinumab

Brand: STELARA

First FDA approval: 2009-09-25

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$2898.19Per unit

Average NADACAcross all dosage forms and strengths

—

$20844.79Up to $29841.65

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$5.16BFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

199K48K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$25,873Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

156Substantial friction

1644Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

6Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

NoBrand-only